Advertisement

TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer

Open AccessPublished:November 21, 2022DOI:https://doi.org/10.1016/j.ctro.2022.11.010

      Highlights

      • There is a lack of prospective level I evidence for the use of PBT for most adult cancers including oropharyngeal squamous cell carcinoma (OPSCC).
      • TORPEdO is the UK’s first PBT clinical trial and aims to determine the benefits of PBT for OPSCC.
      • Training and support has been provided before and during the trial to reduce variations of contouring and radiotherapy planning.
      • There is a strong translational component within TORPEdO. Imaging and physics data along with blood, tissue collection will inform future studies in refining patient selection for IMPT.
      To read this article in full you will need to make a payment
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical and Translational Radiation Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sung H.
        • Ferlay J.
        • Siegel R.
        • Laversanne M.
        • Soerjomataram I.
        • et al.
        Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
        CA Cancer J Clin. 2021; 71: 209-249
      1. Mehanna H, Evans M, Beasley M, Chatterjee S, Dilkes M, et al. Oropharyngeal cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol. 2016 May;130(S2):S90-S96.

        • Nutting C.M.
        • Morden J.P.
        • Harrington K.J.
        • Urbano T.G.
        • Bhide S.A.
        at al Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial.
        Lancet Oncol. 2011 Feb; 12: 127-136
        • Price J.
        • Hall E.
        • West C.
        • Thomson D.
        TORPEdO - A Phase III Trial of Intensity-modulated Proton Beam Therapy Versus Intensity-modulated Radiotherapy for Multi-toxicity Reduction in Oropharyngeal Cancer.
        Clin Oncol (R Coll Radiol). 2020 Feb; 32: 84-88
      2. National Cancer Research Institute Clinical and Translational Radiotherapy Research Working Group (CTRad) Proton Beam Clinical Trial Strategy Group. Proton Beam Therapy – the Challenges of Delivering High-quality Evidence of Clinical Benefit. Clin Oncol (R Coll Radiol). 2018 May;30(5):280-284.

        • Ofuya M.
        • McParland L.
        • Murray L.
        • Brown S.
        • Sebag-Montefiore D.
        • et al.
        Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy.
        Clin Transl Radiat Oncol. 2019 Jul; 12: 17-26
        • Zietman A.L.
        Too Big to Fail? The Current Status of Proton Therapy in the USA.
        Clin Oncol (R Coll Radiol). 2018 May; 30: 271-273
        • Crellin A.
        The Road Map for National Health Service Proton Beam Therapy.
        Clin Oncol (R Coll Radiol). 2018 May; 30: 277-279
        • Langendijk J.A.
        • Doornaert P.
        • Verdonck-de Leeuw I.M.
        • Leemans C.R.
        • Aaronson N.K.
        • et al.
        Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.
        J Clin Oncol. 2008 Aug 1; 26: 3770-3776
        • Patterson J.M.
        • Hildreth A.
        • McColl E.
        • Carding P.N.
        • Hamilton D.
        • et al.
        The clinical application of the 100mL water swallow test in head and neck cancer.
        Oral Oncol. 2011 Mar; 47: 180-184
        • List M.A.
        • Ritter-Sterr C.
        • Lansky S.B.
        A performance status scale for head and neck cancer patients.
        Cancer. 1990 Aug 1; 66: 564-569
        • Blanchard P.
        • Garden A.S.
        • Gunn G.B.
        • Rosenthal D.I.
        • Morrison W.H.
        • et al.
        Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer - A case matched analysis.
        Radiother Oncol. 2016 Jul; 120: 48-55
        • Wopken K.
        • Bijl H.P.
        • Langendijk J.A.
        Prognostic factors for tube feeding dependence after curative (chemo-) radiation in head and neck cancer: A systematic review of literature.
        Radiother Oncol. 2018 Jan; 126: 56-67
      3. Mehta S, Kent Y, McPartlin A, Garcez K, Sykes A et al. Feeding tube dependency at 12 months post treatment in oropharyngeal cancer patient treated with radical intent- a single institute experience. Eur J Surg Oncol. 2018; Volume 44(Supplement 1): S45-S46.

        • Roe J.W.
        • Drinnan M.J.
        • Carding P.N.
        • Harrington K.J.
        • Nutting C.M.
        Patient-reported outcomes following parotid-sparing intensity-modulated radiotherapy for head and neck cancer. How important is dysphagia?.
        Oral Oncol. 2014 Dec; 50: 1182-1187
        • Langendijk J.A.
        • Lambin P.
        • De Ruysscher D.
        • Widder J.
        • Bos M.
        • et al.
        Selection of patients for radiotherapy with protons aiming at reduction of side effects: the model-based approach.
        Radiother Oncol. 2013 Jun; 107: 267-273
      4. Rwigema JC, Langendijk JA, van der Laan HP, Lukens JN, Swisher-McClure SD, et al. Proton Therapy Improves Toxicity for Oropharyngeal Cancer: An Outcomes and Predictive Model-based Approach, International Journal of Radiation Oncology*Biology*Physics, Volume 99, Issue 2, Supplement, 2017, Pages S135-S136.

        • Sharma S.
        • Zhou O.
        • Thompson R.F.
        • Lukens J.N.
        • Lin A.
        • et al.
        A Comparative Study of Patient-Reported Xerostomia and Dysgeusia in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Treated With Volumetric Modulated Arc Therapy (VMAT) or Proton Pencil Beam Scanning (PBS).
        International Journal of Radiation Oncology*Biology*Physics, Volume 93, Issue. 2015; 3: S69-S70
      5. Sharma S, Zhou O, Thompson RF, Lukens JN, Lin A, et al. Correlation of Dosimetric Parameters to Patient-Reported Taste Changes After Radiation for Oropharyngeal Squamous Cell Carcinoma, International Journal of Radiation Oncology*Biology*Physics, Volume 96, Issue 2, Supplement, 2016, Page E354.

      6. Nutting C, Rooney K, Foran B, Pettit L, Beasley M, et al. Results of a randomized phase III study of dysphagia-optimized intensity modulated radiotherapy (Do-IMRT) versus standard IMRT (S-IMRT) in head and neck cancer. Journal of Clinical Oncology 2020 38:15_suppl, 6508-6508.